NEW YORK – 10x Genomics this week closed its initial public offering, with aggregate gross proceeds of $448.5 million, before discounts, commissions, and expenses. The single-cell analysis firm sold 11.5 million shares of its Class A common stock at an offering price of $39.00 per share. The underwriters fully exercised their option to purchase 1.5 million additional shares.
JP Morgan, Goldman Sachs, and Bank of America Merrill Lynch acted as lead joint book-running managers. Cowen acted as lead manager.